Non‐steroidal anti‐inflammatory drugs in management of COVID‐19; A systematic review on current evidence

Abstract

Background

Since there is still no definitive conclusion regarding which non‐steroidal anti‐inflammatory drugs (NSAIDs) are most effective and safe in viral respiratory infections, we decided to evaluate the efficacy and safety of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for coronavirus disease 2019 (COVID‐19).

Methods

A search was performed in Medline (via PubMed), Embase and CENTRAL databases until 23 March 2020. Clinical trials on application of NSAIDs in viral respiratory infections were included.

Results

Six clinical trials were included. No clinical trial has been performed on COVID‐19, Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome infections. Studies show that ibuprofen and naproxen not only have positive effects in controlling cold symptoms, but also do not cause serious side effects in rhinovirus infections. In addition, it was found that clarithromycin, naproxen and oseltamivir combination leads to decrease in mortality rate and duration of hospitalisation in patients with pneumonia caused by influenza.

Conclusion

Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID‐19 and case‐reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID‐19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID‐19 patients until there are enough evidence. Naproxen may be a good choice for future clinical trials.

Review criteria

• A search was performed in Medline (via PubMed), Embase and CENTRAL databases until 23 March 2020.

• Clinical trials on application of non‐steroidal anti‐inflammatory drugs (NSAIDs) in viral respiratory infections were included.

Message for the clinic

• Since there is no clinical trial on coronavirus disease 2019 (COVID‐19) and case‐reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID‐19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID‐19 patients until there are enough evidence.

• Naproxen may be a good choice for future clinical trials.

1. INTRODUCTION

Currently, coronavirus disease 2019 (COVID‐19) pandemic is the most important challenge the healthcare systems all around the world is facing. Despite the daily increase in the number of COVID‐19 cases ¹ and increase in knowledge over COVID‐19, not only no definitive treatment is available for it, but also there is no agreement on its supportive treatment protocol.

Treatments such as antiviral therapy, use of antibiotics, using interferon, corticosteroids and symptomatic treatments such as using anti‐inflammatory and anti‐fever drugs have been mentioned in current guidelines, ² , ³ some of which have been doubted recently. For example using Lopinavir‐Ritonavir has been mentioned as the first line of antiviral therapy in protocols, but a clinical trial on 199 patients shows that the outcome of using this combination therapy in severe COVID‐19 cases is not different than standard treatment. ⁴ On the contrary, a case report on four young patients with no underlying illness showed that prescription of ibuprofen exacerbates the condition of the patients. ⁵ These reports have resulted in studies still seeking the optimum treatment for COVID‐19.

Non‐steroidal anti‐inflammatory drugs (NSAIDs) have been used for management of respiratory infections, controlling fever, reducing chest pain and other symptoms such as cough since a long time ago. ⁶ , ⁷ Many NSAID compounds are available, the most famous of which are ibuprofen, diclofenac, aspirin, naproxen and indomethacin. Some of the compounds in this family have anti‐viral properties in addition to anti‐inflammatory properties, which makes them appropriate for treating viral respiratory infections. ⁸ , ⁹ Although these medications have been used in respiratory infections for years, there is still no definitive conclusion regarding which compound is most effective and safe.

In a case report on four patients with COVID‐19, it was shown that ibuprofen might exacerbate the condition of patients. ⁵ However, some guidelines have recommended prescription of ibuprofen in these patients. ² Therefore, there is still controversy on which NSAID should be used in the treatment protocol of COVID‐19 patients. ¹⁰ , ¹¹ , ¹² Large number of articles have been published on COVID‐19 in the first 3 months of 2020, most of which have focused on epidemiological evaluation and clinical course and treatment of the disease. In the preliminary search performed by the researchers of the present study it was found that the majority of the studies published on COVID‐19 treatment were case‐series and case‐reports and there are few reports on prescription of NSAIDs in these studies. Therefore, in the present systematic review, we decided to evaluate the effectiveness of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for COVID‐19 based on the findings.

2. METHODS

2.1. Study design

The present systematic review aims to evaluate the existing clinical trials on safety and efficacy of using NSAIDs in management of viral respiratory infections. To reach the aims of the present study, a combination of terms related to NSAIDs and viruses causing respiratory infections were used on search databases. Choosing the keywords related to viruses causing respiratory infections was done with the guidance of a respiratory disease specialist and NSAIDs with the consultation of a pharmacologist.

2.2. Selection criteria

In the present study, all clinical trials were included. Animal studies, in vitro evaluations, non‐viral infections, non‐respiratory infections, observational studies and review studies were excluded.

2.3. Search strategy

A search was performed from the establishment of the database until 23 March 2020. The studied databases included Medline (via PubMed), Embase and CENTRAL. Keywords related to respiratory viruses in combination with NSAIDs were selected based on expert opinion using MeSH and Emtree on Medline and Embase databases and the titles of related articles.

The search strategy used for searching in Medline database has been reported in Appendix A. In addition to the systematic search, a manual search was performed via Google and Google Scholar search engines, and in bibliography of related articles.

2.4. Data gathering

Records were saved in Endnote X7 and duplicates were removed. In the next step, initial screening was performed by two independent researchers. Then, articles were selected based on the inclusion and exclusion criteria, and data were summarised in a checklist by two independent researchers. The gathered data consisted of name of the first author, year of publication, country in which the study was performed, type of study, sample size, age and sex distribution of the patients, name of the virus causing respiratory infection, name of the NSAIDs, dose and duration of prescription, route of administration and treatment outcome. Any disagreement was resolved through discussion with a third reviewer.

2.5. Risk of bias assessment of the studies

Quality control of the studies was performed based on the guidelines of Cochrane Collaboration's tool for assessing risk of bias in randomised trials. ¹³

3. RESULTS

3.1. Study selection and characteristics

The performed search yielded 1033 non‐duplicate articles. Out of which, six clinical trials were finally included in the present study ¹⁴ , ¹⁵ , ¹⁶ , ¹⁷ , ¹⁸ , ¹⁹ (Figure 1). These studies included 845 adult patients (46.9% male). The studied viruses were rhinovirus in four studies, Influenza type A (H3 N2) in one study and unknown in one study. The NSAIDs applied were naproxen in three studies, aspirin in one study and ibuprofen in two studies. Route of administration was oral in all the studies. The control group was placebo in five studies and oseltamivir in one study. Duration of treatment varied between 4 and 14 days. In three studies, other drugs were used as combination therapy along with NSAIDs. Table 1 depicts the characteristics of the included studies.

Figure 1.

Flow diagram of the present systematic review

Table 1.

Clinical studies that reported the use of non‐steroidal anti‐inflammatory drugs (NSAIDs) in management of viral respiratory infections

First author; year; country	Study type	Sample size	Age (y) a	Male	Subjects	Treatment groups	Treated patients (n)	Dosage (daily)	Route of administration	Duration of treatment	Combination	Main findings
Rhinovirus
Graham; 1990; Australia 16	RCT	60	18‐30	34	Rhinovirus infected	Aspirin, Acetaminophen, Ibuprofen Placebo	15 15 15 15	4 g 4 g 1.2 g	Oral	14 d	No	Aspirin and acetaminophen suppressed serum neutralising antibody response and increased patients’ nasal symptoms. Viral shedding was not significantly different.
Gwaltney; 1992; USA 18	RCT	24	21.4	14	Rhinovirus infected	Naproxen Placebo	16 8	500 mg loading dose, and then, 750 mg for naproxen	Oral	4 d	INF‐α2b and Ipratropium	Combination of naproxen, INF‐α2b and Ipratropium reduced viral shedding time. Virus titter was lower in treated group. Serum antibody responses and antibody titters were not significantly different. The cold symptoms were reduced in treated subject.
Sperbert; 1989; USA 15	RCT	49	20.5	NR	Rhinovirus infected	Ibuprofen Pseudoephedrine Placebo	18 22 9	0.8 g 240 mg NA	Oral	4 d	Pseudoephedrine	Illness severity and total symptoms score was reduced in both treated groups compared with placebo. There was no adverse effect directly attributable to ibuprofen.
Sperbert; 1992; USA 17	RCT	79	21.4	47	Rhinovirus infected	Naproxen Placebo	39 40	400 mg loading dose, and then, 600‐1500 mg for naproxen	Oral	5 d	No	There was no significant difference in the viral titters and serum antibody responses between the two groups. Symptoms score had significantly improved in naproxen group.
Influenza
Hung; 2016; Hong Kong 14	RCT	217	80 (72‐85) 81.5 (71‐87.3)	116	Influenza A (H3 N2) infected with pneumonia	Naproxen oseltamivir	107 110	1 g daily	Oral	5 d	Clarithromycin and oseltamivir	Combination treatment of clarithromycin, naproxen and oseltamivir compared with oseltamivir alone significantly reduced 30‐day and 90‐day mortality, and length of hospital stay.
Non‐specified
Llor; 2013; Spain 19	RCT	416	18‐70	185	Non‐pneumonic acute bronchitis	Ibuprofen Amoxicillin‐clavulanic acid Placebo	136 137 143	1.8 g 1.5 g‐375 mg NA	Oral	10 d	No	There is no significant difference in the number of days with cough between groups. Adverse events were more common in antibiotic group than ibuprofen (5%) and placebo (3%).

Abbreviations: CT, computed tomography; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IMV, invasive mechanical ventilation; NR, not reported.

^a Age was reported as range, mean ± SD or median (interquartile range [IQR]).

3.2. Risk of bias assessment of the articles

Risk of bias assessment showed that random sequence generation, blinding of participants and personnel, and other bias had low risk of bias in all studies. Allocation concealment was unclear in two studies. Selective reporting was also unclear in four studies. Finally, blinding of outcome assessment in two studies and incomplete outcome assessment in one study were categorised as high risk (Table 2).

Table 2.

Risk of bias assessment

✓ Low risk × High risk ? Unclear	Graham; 1990	Gwaltney; 1992	Hung; 2016	Llor; 2013	Sperbert; 1989	Sperbert; 1992
Random sequence generation	✓	✓	✓	✓	✓	✓
Allocation concealment	?	?	✓	✓	✓	✓
Blinding of participants and personnel	✓	✓	✓	✓	✓	✓
Blinding of outcome assessment	✓	✓	×	×	✓	✓
Incomplete outcome assessment	✓	×	✓	✓	✓	✓
Selective reporting	?	?	✓	✓	?	?
Other bias	✓	✓	✓	✓	✓	✓

3.3. The effect of NSAIDs prescription on viral respiratory infection

The included clinical trials had studied different NSAIDs and they had different findings. In the first study, in 1990, Garaham et al performed a clinical trial on 34 healthy volunteers and after infecting them with rhinovirus showed that prescription of aspirin and acetaminophen could inhibit serum neutralising antibody response and increase the respiratory symptoms of these patients. However, these variables were not different from those of the placebo group with ibuprofen prescription. In addition there was no difference in viral shedding between the groups under treatment with acetaminophen, aspirin and ibuprofen combination and placebo. ¹⁶ In another study, in 1992, Gwaltney performed a similar study on healthy volunteers and showed that naproxen, interferon‐α2b and ipratropium combination therapy led to decrease in the time of viral shedding and alleviation of the symptoms of cold. In addition, viral titters in this group was lower than the placebo group. However, antibody responses and antibody titters were not different between the two groups. ¹⁸ Yet, it is not known that the observed effects are because of naproxen or interferon‐α2b and ipratropium. Anyhow, it seems that naproxen does not cause serious side effects in patients affected with rhinovirus.

In addition, in 1989, Sperber et al studied patients with rhinovirus and showed that oral prescription of ibuprofen decreases the severity of the disease and alleviates cold symptoms in patients compared with the placebo group. Prescription of ibuprofen had no side effects in the studied patients. ¹⁵ The same researchers performed another study with similar design in 1992 studying naproxen and showed that 5‐day prescription of naproxen alleviated cold symptoms compared with placebo but had no effect in viral titter and serum antibody responses. ¹⁷

3.4. Influenza type A

In their study on 217 Influenza A (H3 N2) patients with pneumonia, Hung et al compared clarithromycin‐naproxen‐oseltamivir combination therapy with oseltamivir alone and expressed that 5‐day therapy with these drugs leads to decrease in 30‐day and 90‐day mortality of patients as well as duration of hospitalisation. ¹⁴

3.5. Other viral infection

In 2013, Llor et al studied patients with‌ non‐pneumonic acute bronchitis and expressed that prescription of ibuprofen does not have any effect on the number of daily coughs of patients during 10 days. The rate of adverse effects was reported to be 5% in ibuprofen group and 3% in placebo group. ¹⁹

3.6. COVID‐19

In evaluating the effectiveness of NSAIDs prescription in management of COVID‐19, no study was found to point to using these drugs. In the search performed, one clinical trial was found on the effect of prescribing antiviral therapy in management of COVID‐19, which had not mentioned prescription of NSAIDs. ⁴

3.7. Middle East respiratory syndrome and severe acute respiratory syndrome

No clinical trial was found with the aim of evaluating the effectiveness or safety of NSAIDs prescription in management of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) patients.

4. DISCUSSION

The present systematic review aimed to evaluate the existing evidence regarding use of NSAIDs in management of viral respiratory. The findings of the present study showed that no clinical trial was performed on patients with COVID‐19, SARS and MERS with this aim. Regarding rhinoviruses, three studies have reported that ibuprofen and naproxen not only have positive effects in controlling cold symptoms, but also do not cause serious side effects. Another clinical trial, which evaluated the effect of clarithromycin, naproxen and oseltamivir combination on pneumonia caused by influenza, showed that this treatment leads to decrease in mortality rate and duration of hospitalisation.

Recently, in a case report, it was revealed that ibuprofen prescription exacerbated the condition of four patients with COVID‐19 and this led the researchers to recommend not consuming it. ⁵ For further investigation, the researchers of the present study evaluated all the existing reports on treatment of COVID‐19 patients, which led to finding one clinical trial ⁴ and 12 case‐report/case‐series studies. ¹ , ³ , ²⁰ , ²¹ , ²² , ²³ , ²⁴ , ²⁵ , ²⁶ , ²⁷ , ²⁸ , ²⁹ , ³⁰ , ³¹ , ³² , ³³ , ³⁴ There was no mention of prescribing NSAIDs in any of these studies. This might be because of no NSAID being prescribed, which is very unlikely; or it might just be that the authors did not point out prescribing NSAIDs. In this regard, it is better that researchers of these studies indicate if they have used NSAIDs in treating the patients or not through a letter to editor or commentary. Further searches revealed that in a study, Jin et al attempted to provide a treatment guideline for COVID‐19 patients. In this study, use of ibuprofen has been suggested for controlling the patients’ fever (fever over 38.5° Celsius). The researchers of the study express that at the time of designing the study, there was not sufficient evidence on COVID‐19. Therefore, the guideline was prepared based on the studies performed on SARS, MERS and Influenza. ² Based on the search performed for the present systematic review, no clinical trial has been performed on use of NSAIDs in patients with SARS and MERS. Only one study has been performed on influenza type A (H3 N2), which has reported mild to moderate efficacy for naproxen. Therefore, it seems that suggesting consumption of ibuprofen in the mentioned guideline is based on evidence presented in observational studies and not well‐designed clinical trials.

Since the pathophysiology and transmission of COVID‐19 is different from other viruses and it shows significant differences even with other viruses in the same family, such as SARS and MERS, the findings of the studies performed on other viruses may not be generalisable to COVID‐19. In addition, since a case‐report has been recently published that recommended not using ibuprofen in COVID‐19, NSAIDs should be used with caution. Naproxen could be a proper substitute for ibuprofen for controlling patients’ fever. In the clinical trials included in this study naproxen was found to be an effective and safe drug for controlling viral respiratory infections. In addition, there are pre‐clinical evidence that indicate the antiviral properties of naproxen. For instance, Zheng et al showed that naproxen shows wide‐spectrum antiviral effects in mice with influenza. ⁸ Naproxen inhibits nucleoprotein binding to RNA and consequently inhibits replication in viruses. ³⁵ Since COVID‐19 is an RNA virus, it seems that naproxen is a good option for treating the fever caused by COVID‐19 infection. Therefore, there is a need for designing clinical trials to evaluate the safety and efficacy of naproxen in management of COVID‐19 patients.

5. CONCLUSION

Findings of the present study showed that no clinical trial has been performed with the aim of assessing the efficacy and safety of using NSAIDs in COVID‐19, SARS and MERS infections. In the clinical trials performed on rhinovirus and influenza type A, naproxen has been introduced as a safe and effective treatment for management of respiratory infections. Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID‐19 in this regard and case‐reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID‐19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID‐19 patients until there are enough evidence. For performing clinical trials in patients with COVID‐19, naproxen can be a good candidate. Naproxen may be a good choice for future clinical trials.

DISCLOSURE

There is no conflict of interest.

AUTHORS’ CONTRIBUTION

Study design: SS, MY and AZ; Data gathering: MY, AfZ and SS; Interpreting the findings: All authors; Writing the first draft: MY, AMN and SS; Critically revised the manuscript: All authors.

APPENDIX A.

SEARCH QUERIES IN MEDLINE DATABASE

(((randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh]))) AND (((“Anti‐Inflammatory Agents, Non‐Steroidal”[mh] OR “Cyclooxygenase Inhibitors”[mh] OR “Cyclooxygenase 2 Inhibitors”[mh] OR “Diclofenac “[mh] OR “Ibuprofen “[mh] OR “Indomethacin”[mh] OR “Naproxen”[mh] OR NSAIDs[tiab] OR Non‐Steroidal Anti‐Inflammatory Agents[tiab] OR Diclofenac [tiab] OR Ibuprofen [tiab] OR Indomethacin[tiab] OR Naproxen[tiab])) AND (“Pneumonia”[mh] OR “Pleuropneumonia”[mh] OR “Bronchopneumonia”[mh] OR “Healthcare‐Associated Pneumonia”[mh] OR “Pleuropneumonia”[mh] OR “Pneumonia, Viral”[mh] OR “Respiratory Syncytial Viruses”[mh] OR “Respiratory Syncytial Virus Infections”[mh] OR “Respiratory Syncytial Virus, Human”[mh] OR “Respiratory Syncytial Virus, Bovine”[mh] OR “Rhinovirus”[mh] OR “Influenza, Human”[mh] OR “Influenza A Virus, H10N8 Subtype”[mh] OR “Influenza A Virus, H7N9 Subtype”[mh] OR “Influenza A Virus, H10N7 Subtype”[mh] OR “Influenza A Virus, H7N3 Subtype”[mh] OR “Influenza A Virus, H7N2 Subtype”[mh] OR “Influenza A Virus, H7N1 Subtype”[mh] OR “Influenza A Virus, H1N2 Subtype”[mh] OR “Influenza A Virus, H9N2 Subtype”[mh] OR “Influenza A Virus, H7N7 Subtype”[mh] OR “Influenza A Virus, H5N2 Subtype”[mh] OR “Influenza A Virus, H3N2 Subtype”[mh] OR “Influenza A Virus, H2N2 Subtype”[mh] OR “Influenza A Virus, H1N1 Subtype”[mh] OR “Influenza A Virus, H5N8 Subtype”[mh] OR “Influenza B virus”[mh] OR “Influenzavirus C”[mh] OR “Influenza A virus”[mh] OR “Metapneumovirus”[mh] OR “Parainfluenza Virus 2, Human”[mh] OR “Parainfluenza Virus 3, Bovine”[mh] OR “Bocavirus”[mh] OR “Human bocavirus”[mh] OR “Coronavirus”[mh] OR “Middle East Respiratory Syndrome Coronavirus”[mh] OR “Coronavirus NL63, Human”[mh] OR “Porcine Respiratory Coronavirus”[mh] OR “Coronavirus OC43, Human”[mh] OR “Coronavirus 229E, Human”[mh] OR “Coronavirus Infections”[mh] OR “Coronavirus, Turkey”[mh] OR “Severe Acute Respiratory Syndrome”[mh] OR “SARS Virus”[mh] OR “Alphacoronavirus”[mh] OR “Adenoviridae Infections”[mh] OR “Adenoviridae”[mh] OR “Adenovirus Infections, Human”[mh] OR “Enterovirus”[mh] OR “Enterovirus A, Human”[mh] OR “Enterovirus B, Human”[mh] OR “Echovirus 6, Human”[mh] OR “Echovirus 9”[mh] OR “Enterovirus C, Human”[mh] OR “Enterovirus D, Human”[mh] OR “Herpesvirus 3, Human”[mh] OR “Varicella Zoster Virus Infection”[mh] OR “Hantavirus”[mh] OR “Hantavirus Pulmonary Syndrome”[mh] OR “Hantavirus Infections”[mh] OR “Epstein‐Barr Virus Infections”[mh] OR “Herpesvirus 4, Human”[mh] OR “Parechovirus”[mh] OR “Simplexvirus”[mh] OR “Cytomegalovirus”[mh] OR “Cytomegalovirus Infections”[mh] OR “Measles”[mh] OR “Measles virus”[mh] OR “Morbillivirus”[mh] OR “Morbillivirus Infections”[mh] OR Pneumonitis[tiab] OR Pulmonary Inflammation[tiab] OR Pulmonary Inflammations[tiab] OR Lung Inflammation[tiab] OR Lung Inflammations[tiab] OR Viral Pneumonia[tiab] OR Respiratory Syncytial Virus[tiab] OR Rhinovirus[tiab] OR Coryza Virus[tiab] OR Common Cold Virus[tiab] OR Human Influenzas[tiab] OR Influenza[tiab] OR Influenzas[tiab] OR Human Flu[tiab] OR Flu, Human[tiab] OR Human Influenza[tiab] OR Influenza in Humans[tiab] OR Influenza in Human[tiab] OR Influenza A Virus[tiab] OR H10N8[tiab] OR H7N9 [tiab] OR H10N7 [tiab] OR H7N3 [tiab] OR H7N2 [tiab] OR H7N1 [tiab] OR H1N2 [tiab] OR H9N2 [tiab] OR H7N7 [tiab] OR H5N2 [tiab] OR H3N2 [tiab] OR H2N2 [tiab] OR H1N1[tiab] OR H5N8 [tiab] OR Influenza B virus[tiab] OR Orthomyxovirus Type B[tiab] OR Influenza Virus Type B[tiab] OR Influenza A virus[tiab] OR Influenza Virus Type A[tiab] OR Orthomyxovirus Type A[tiab] OR Orthomyxovirus Type C[tiab] OR Influenza Virus Type C[tiab] OR Influenza C Virus[tiab] OR Influenza C Viruses[tiab] OR avian flu[tiab] OR swine flu[tiab] OR Metapneumovirus[tiab] OR Avian Pneumovirus[tiab] OR Avian Metapneumovirus[tiab] OR Turkey Rhinotracheitis Virus[tiab] OR Human Metapneumoviruses[tiab] OR Human Metapneumovirus[tiab] OR Parainfluenza[tiab] OR Bocavirus[tiab] OR MERS‐CoV[tiab] OR MERS Virus[tiab] OR MERS Viruses[tiab] OR Virus, MERS[tiab] OR MERS[tiab] OR Middle East respiratory syndrome‐related coronavirus[tiab] OR Middle East respiratory syndrome‐related coronavirus[tiab] OR Middle East Respiratory Syndrome Coronavirus[tiab] OR NL63[tiab] OR HCoV‐NL63[tiab] OR Human Coronavirus NL63[tiab] OR HCoV‐OC43[tiab] OR HCoV‐229E[tiab] OR Severe Acute Respiratory Syndrome Virus[tiab] OR SARS‐Related Coronavirus[tiab] OR Coronavirus, SARS‐Related[tiab] OR SARS‐Related Coronavirus[tiab] OR SARS‐CoV[tiab] OR Urbani SARS‐Associated Coronavirus[tiab] OR Coronavirus, Urbani SARS‐Associated[tiab] OR SARS‐Associated Coronavirus, Urbani[tiab] OR Urbani SARS‐Associated Coronavirus[tiab] OR SARS Coronavirus[tiab] OR Coronavirus, SARS[tiab] OR Severe acute respiratory syndrome‐related coronavirus[tiab] OR Severe acute respiratory syndrome‐related coronavirus[tiab] OR SARS‐Associated Coronavirus[tiab] OR Coronavirus, SARS‐Associated[tiab] OR SARS‐Associated Coronavirus[tiab] OR SARS[tiab] OR Alphacoronavirus[tiab] OR Adenoviridae[tiab] OR Adenovirus[tiab] OR Enterovirus[tiab] OR Herpesvirus[tiab] OR Varicella Zoster[tiab] OR Hantavirus[tiab] OR EBV Infections[tiab] OR Epstein‐Barr Virus[tiab] OR Herpesvirus[tiab] OR Parechovirus[tiab] OR Herpes simplex virus[tiab] OR Cytomegalovirus[tiab] OR Measles[tiab] OR Rubeola[tiab] OR Morbillivirus[tiab])).

Yousefifard M, Zali A, Zarghi A, Madani Neishaboori A, Hosseini M, Safari S. Non‐steroidal anti‐inflammatory drugs in management of COVID‐19; A systematic review on current evidence. Int J Clin Pract. 2020;74:e13557. 10.1111/ijcp.13557